Divalproex Sodium in Substance Abusers With Mood Disorder.
J Clin Psychiatry 2000;61:916-921
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Substance abuse is a common comorbid
illness in patients with mood disorders. Little has been written
about the pharmacologic treatment of patients with affective
lability and co-occurring substance abuse, however. The following
report will describe clinical experience using divalproex sodium
in substance-abusing patients with mood disorder.
Method: Twenty patients admitted to an
intermediate-care inpatient substance abuse program were
diagnosed with comorbid mood disorder (according to DSM-IV
criteria) and treated with divalproex sodium in an open-label,
naturalistic trial with no blind. All patients were followed
clinically and were assessed using the Clinical Global
Impressions scale (CGI) and laboratory studies.
Results: Seven patients referred while on
divalproex treatment continued to exhibit improved mood. Eleven
others had at least 1 week of follow-up, and 10 of these also
showed improvement. In 13 cases, divalproex was used safely with
other psychiatric medications. Two patients complained of slight
tremor, 1 of whom was also taking fluoxetine. Fifteen of 17
patients in whom biochemistry and hematology laboratory studies
were completed had unremarkable results; 2 other patients had
pretreatment abnormalities, which worsened over the course of
treatment. Mean plasma valproate level was 58.53 micrograms/mL.
Mean length of follow-up was 38 days. Mean period of abstinence
prior to starting medication was 48 days. Some patients reported
decreased cravings, and, by self-report, all patients remained
Conclusion: This report suggests that divalproex
sodium is efficacious and safe, both alone and in combination
with other psychiatric medications, in treating substance-abusing
patients with mood disorder.